Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
28 Oct 2022 07:00 AM
RNS
Block Listing Six Monthly Return
20 Oct 2022 08:01 AM
RNS
Director/PDMR Shareholding
20 Oct 2022 08:01 AM
RNS
Admission of the Company's Ordinary Shares
20 Oct 2022 07:00 AM
RNS
Posting of the Company's Open Offer Circular
18 Oct 2022 11:49 AM
RNS
Result of Placing
18 Oct 2022 09:16 AM
RNS
Private CB and ABB Launch
18 Oct 2022 09:14 AM
RNS
Proposed acquisition of Launch Diagnostics
29 Sep 2022 07:00 AM
RNS
Interim Results for the Period Ended 30 June 2022
26 Sep 2022 07:00 AM
RNS
Notice of Results
05 Sep 2022 07:00 AM
RNS
AVA6000 receives Orphan Drug Designation from FDA
01 Sep 2022 07:00 AM
RNS
Phase I study of AVA6000 advances to fourth cohort
21 Jul 2022 07:00 AM
RNS
AffyXell successfully completes funding round
30 Jun 2022 07:00 AM
RNS
LG Chem renews license triggers payment to Avacta
29 Jun 2022 09:05 AM
RNS
Second Price Monitoring Extn
29 Jun 2022 09:00 AM
RNS
Price Monitoring Extension
29 Jun 2022 07:00 AM
RNS
Second dose escalation in phase 1 trial of AVA6000
23 Jun 2022 04:41 PM
RNS
Second Price Monitoring Extn
23 Jun 2022 04:36 PM
RNS
Price Monitoring Extension
23 Jun 2022 04:27 PM
RNS
Result of Annual General Meeting
16 Jun 2022 04:41 PM
RNS
Second Price Monitoring Extn
16 Jun 2022 04:36 PM
RNS
Price Monitoring Extension
31 May 2022 07:00 AM
RNS
Posting of Annual Report and Notice of AGM
16 May 2022 12:00 PM
RNS
AffyXell expands partnership with GenScript ProBio
11 May 2022 07:00 AM
RNS
London Therapeutics headquarters established
06 May 2022 07:00 AM
RNS
Block Listing Application to AIM (update)
28 Apr 2022 01:53 PM
RNS
Block Listing Application to AIM
14 Apr 2022 05:01 PM
RNS
Issue of Equity and Total Voting Rights
14 Apr 2022 11:29 AM
RNS
Issue of Equity and Total Voting Rights
13 Apr 2022 07:00 AM
RNS
AffyXell milestone and increased equity stake
12 Apr 2022 07:00 AM
RNS
Poster presented at the AACR available to download
11 Apr 2022 04:41 PM
RNS
Second Price Monitoring Extn
11 Apr 2022 04:35 PM
RNS
Price Monitoring Extension
11 Apr 2022 02:05 PM
RNS
Second Price Monitoring Extn
11 Apr 2022 02:00 PM
RNS
Price Monitoring Extension
08 Apr 2022 01:57 PM
RNS
Issue of Equity and Total Voting Rights
08 Apr 2022 07:00 AM
RNS
AffyXell partners with Biocytogen and KNTSC
07 Apr 2022 04:31 PM
RNS
Issue of Equity and Total Voting Rights
06 Apr 2022 07:00 AM
RNS
Preliminary Results
30 Mar 2022 04:41 PM
RNS
Second Price Monitoring Extn
30 Mar 2022 04:35 PM
RNS
Price Monitoring Extension
30 Mar 2022 07:00 AM
RNS
Notice of Results and Investor Presentation
29 Mar 2022 07:00 AM
RNS
AVA6000 data poster presentation at AACR
21 Mar 2022 07:00 AM
RNS
Directorate Change
16 Mar 2022 07:00 AM
RNS
Vimian acquires Avacta's Animal Health Division
14 Feb 2022 04:41 PM
RNS
Second Price Monitoring Extn
14 Feb 2022 04:36 PM
RNS
Price Monitoring Extension
07 Feb 2022 04:36 PM
RNS
Price Monitoring Extension
03 Feb 2022 05:26 PM
RNS
Issue of Equity and Total Voting Rights
03 Feb 2022 04:41 PM
RNS
Second Price Monitoring Extn
03 Feb 2022 04:35 PM
RNS
Price Monitoring Extension

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100